PT - JOURNAL ARTICLE AU - Steven Sanche AU - Tyler Cassidy AU - Pinghan Chu AU - Alan S. Perelson AU - Ruy M. Ribeiro AU - Ruian Ke TI - A simple model of COVID-19 explains disease severity and the effect of treatments AID - 10.1101/2021.11.29.21267028 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.29.21267028 4099 - http://medrxiv.org/content/early/2021/12/02/2021.11.29.21267028.short 4100 - http://medrxiv.org/content/early/2021/12/02/2021.11.29.21267028.full AB - Considerable effort was made to better understand why some people suffer from severe COVID-19 while others remain asymptomatic. This has led to important clinical findings; people with severe COVID-19 generally experience persistently high levels of inflammation, slower viral load decay, display a dysregulated type-I interferon response, have less active natural killer cells and increased levels of neutrophil extracellular traps. How these findings are connected to the pathogenesis of COVID-19 remains unclear. We propose a mathematical model that sheds light on this issue. The model focuses on cells that trigger inflammation through molecular patterns: infected cells carrying pathogen-associated molecular patterns (PAMPs) and damaged cells producing damage-associated molecular patterns (DAMPs). The former signals the presence of pathogens while the latter signals danger such as hypoxia or the lack of nutrients. Analyses show that SARS-CoV-2 infections can lead to a self-perpetuating feedback loop between DAMP expressing cells and inflammation. It identifies the inability to quickly clear PAMPs and DAMPs as the main contributor to hyperinflammation. The model explains clinical findings and the conditional impact of treatments on disease severity. The simplicity of the model and its high level of consistency with clinical findings motivate its use for the formulation of new treatment strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was performed under the auspices of the US Department of Energy through Los Alamos National Laboratory, which is operated by Triad National Security, LLC for the National Nuclear Security Administration of the U.S. Department of Energy (contract No. 89233218CNA000001). The work was supported by the Laboratory Directed Research and Development program of Los Alamos National Laboratory (projects No. 20200743ER, 20200695ER, and 20210730ER), by NIH grants R01-AI028433, R01-OD011095 (ASP), R01-AI15270301 (RK), by the Defense Advanced Research Projects Agency (contract No. W911NF-17-2-0034) and by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE National Laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act. Additional support was provided by the Center for Nonlinear Studies at Los Alamos National Laboratory.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.